Chronic Hepatitis

Top Story

Suboptimal response in HCV genotype 4 in Egypt driven by noncompliance

April 29, 2016

Suboptimal treatment response in chronic HCV genotype 4 in Egypt was driven primarily by noncompliance as well as gaps in the health care system that lead to treatment discontinuation, according to recent findings published in Journal of Viral Hepatitis.

“In Egypt, the national program for HCV treatment has provided a rich pool of data which have led to the conduction of large population-based studies,” the researchers wrote. “This is one of the largest studies examining HCV treatment effectiveness.”

In the Journals

Mothers receive inadequate systemic HBV care following pregnancy

April 27, 2016
A majority of mothers with chronic hepatitis B virus infection post-pregnancy received inadequate care, especially in terms of timely liver function test measurements…
Meeting News Coverage

WHO issues updated HCV guidelines for treatment

April 27, 2016
BARCELONA — Due to the rapid development and evolution of direct-acting viral treatments, WHO issued updated guidelines for the screening, care and treatment of…
Breaking News

FDA approves supplemental NDA for Viekira Pak for HCV genotype 1b

April 25, 2016
AbbVie announced the FDA has approved its supplemental New Drug Application for the use of Viekira Pak without ribavirin for the treatment of adults with genotype 1b…
CME Video

Case Challenges in Pediatric Fatty Liver: What to Look For and When to Refer

This activity is supported by an educational grant from Synageva BioPharma Corp.

Non-alcoholic fatty liver disease (NAFLD) is characterized by excess fat deposition in the liver due to causes other…
More »
Video
Meeting News Coverage

New HCV treatments could reduce mortality, but increase costs by billions

November 19, 2014
More »
Featured
Highlights from International Liver Congress

Highlights from International Liver Congress

In the Journals

Suboptimal response in HCV genotype 4 in Egypt driven by noncompliance

April 29, 2016
Suboptimal treatment response in chronic HCV genotype 4 in Egypt was driven primarily by noncompliance as well as gaps in the health care system that…
In the Journals

Mothers receive inadequate systemic HBV care following pregnancy

April 27, 2016
A majority of mothers with chronic hepatitis B virus infection post-pregnancy received inadequate care, especially in terms of timely liver function…
Meeting News Coverage

WHO issues updated HCV guidelines for treatment

April 27, 2016
BARCELONA — Due to the rapid development and evolution of direct-acting viral treatments, WHO issued updated guidelines for the screening, care…
Breaking News

FDA approves supplemental NDA for Viekira Pak for HCV genotype 1b

April 25, 2016
AbbVie announced the FDA has approved its supplemental New Drug Application for the use of Viekira Pak without ribavirin for the treatment of adults…
Meeting News Coverage

Top HCV stories from International Liver Congress

April 22, 2016
Healio.com/Hepatology and HCV Next have compiled a list of the latest, most relevant research on hepatitis C virus infection, presented recently at…
Meeting News Coverage

Zepatier safe, efficacious in general, problematic HCV patient populations

April 21, 2016
BARCELONA, Spain — Data from a phase 3 trial presented at the International Liver Congress suggested that Zepatier is noninferior to and better…
Editorial

Experts Discuss the Latest Trends in HBV

Healio Gastroenterology, April 2016
While hepatitis B virus continues to be a major global health problem, incidence in the U.S. has significantly declined since the introduction of the…
Cover Story

HBV in US Households: Incidence Decreases as Prevalence Increases

Healio Gastroenterology, April 2016
The National Health and Nutrition Examination Survey indicated that 704,000 adults in the U.S. had hepatitis B virus infection between 1999 and 2008…
Meeting News Coverage

Third phase 3 trial shows HEPLISAV-B vaccine safe, effective against HBV

April 20, 2016
BALTIMORE — Results from the HBV-23 phase 3 trial show that the investigational hepatitis B vaccine HEPLISAV-B provided statistically…
In the Journals

Plasma-derived HBV vaccine induces long-term protection

April 19, 2016
Data recently published in The Journal of Infectious Diseases suggested that plasma-derived hepatitis B vaccination could provide cellular immunity…
More Headlines »
morganatic-roan